Franklin Resources Inc. Grows Stake in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)

Franklin Resources Inc. grew its holdings in shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 3.1% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 4,137,567 shares of the company's stock after buying an additional 125,519 shares during the period. Franklin Resources Inc. owned 6.06% of EyePoint Pharmaceuticals worth $30,825,000 as of its most recent SEC filing.

Several other hedge funds have also recently made changes to their positions in the business. Teacher Retirement System of Texas increased its position in EyePoint Pharmaceuticals by 22.4% during the 4th quarter. Teacher Retirement System of Texas now owns 15,192 shares of the company's stock valued at $113,000 after purchasing an additional 2,782 shares during the period. Swiss National Bank increased its position in shares of EyePoint Pharmaceuticals by 3.5% during the fourth quarter. Swiss National Bank now owns 100,000 shares of the company's stock valued at $745,000 after buying an additional 3,400 shares during the period. China Universal Asset Management Co. Ltd. raised its stake in EyePoint Pharmaceuticals by 40.6% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 14,472 shares of the company's stock worth $108,000 after buying an additional 4,179 shares in the last quarter. Cyndeo Wealth Partners LLC lifted its holdings in EyePoint Pharmaceuticals by 35.5% in the fourth quarter. Cyndeo Wealth Partners LLC now owns 16,990 shares of the company's stock worth $127,000 after buying an additional 4,450 shares during the period. Finally, Wellington Management Group LLP boosted its position in EyePoint Pharmaceuticals by 3.2% during the 4th quarter. Wellington Management Group LLP now owns 177,316 shares of the company's stock valued at $1,321,000 after acquiring an additional 5,552 shares in the last quarter. 99.41% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

EYPT has been the topic of several recent research reports. Chardan Capital reaffirmed a "buy" rating and issued a $33.00 price target on shares of EyePoint Pharmaceuticals in a research note on Thursday, March 6th. StockNews.com raised shares of EyePoint Pharmaceuticals to a "sell" rating in a research note on Friday, March 14th. Citigroup initiated coverage on shares of EyePoint Pharmaceuticals in a research note on Tuesday, January 7th. They set a "buy" rating and a $33.00 target price for the company. Finally, HC Wainwright restated a "buy" rating and issued a $22.00 price target on shares of EyePoint Pharmaceuticals in a research note on Thursday, March 6th. One research analyst has rated the stock with a sell rating and nine have given a buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $26.63.

EyePoint Pharmaceuticals Trading Down 5.6 %

EYPT traded down $0.26 during trading on Thursday, hitting $4.32. 257,245 shares of the company's stock traded hands, compared to its average volume of 904,573. The stock has a market capitalization of $296.57 million, a price-to-earnings ratio of -2.16 and a beta of 1.39. EyePoint Pharmaceuticals, Inc. has a 12-month low of $3.91 and a 12-month high of $23.65. The company's 50 day simple moving average is $6.13 and its two-hundred day simple moving average is $7.95.

EyePoint Pharmaceuticals (NASDAQ:EYPT - Get Free Report) last posted its earnings results on Wednesday, March 5th. The company reported ($0.64) earnings per share for the quarter, missing analysts' consensus estimates of ($0.54) by ($0.10). EyePoint Pharmaceuticals had a negative net margin of 226.57% and a negative return on equity of 43.01%. The firm had revenue of $11.60 million during the quarter, compared to the consensus estimate of $11.02 million. On average, equities analysts expect that EyePoint Pharmaceuticals, Inc. will post -2.13 EPS for the current year.

EyePoint Pharmaceuticals Profile

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.